Results 201 to 210 of about 33,833 (238)

Vitamin C potentiates the killing of Mycobacterium tuberculosis by bedaquiline through metabolic disruption

mBio
Tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), continues to pose a major global health threat, exacerbated by the emergence of drug-resistant strains and the lengthy treatment regimens required for effective ...
C. Vilchèze, S. Rajagopalan, Raja Sab Kalluru, Niaz Banaei, William R. Jacobs   +4 more
semanticscholar   +1 more source

Development and validation of an LC-MS/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Dried blood spot (DBS) assays to quantify novel and repurposed drugs for the treatment of rifampicin-resistant tuberculosis (RR-TB) would facilitate pharmacokinetic studies and therapeutic drug monitoring in low-middle income settings, considering their ...
Gerard Aime Kenfack Teponnou, A. Joubert, Saskia Spaltman, Marthinus van der Merwe, Edda Zangenberg, Sharon Sawe, P. Denti, Sandra Castel, Francesca Conradie, R. Court, G. Maartens, L. Wiesner   +11 more
semanticscholar   +1 more source

Effect of High‐Fat Diets on the Pharmacokinetics of Bedaquiline Fumarate Tablet: A Trial in Healthy Chinese Participants

Clinical pharmacology in drug development
Bedaquiline is employed to treat multidrug‐resistant and extensive drug‐resistant tuberculosis by inhibiting the proton pump of adenosine triphosphate synthase in Mycobacterium tuberculosis.
Xuanxuan Wang, Xiaoyu Zhao, Shaomei Yang, K. He, Qing Wen, Wenyu Zhang   +5 more
semanticscholar   +1 more source

Bedaquiline

Reactions Weekly, 2021
  +5 more sources

Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid.

Journal of Medicinal Chemistry
Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis (anti-TB) treatment regimens and have emerged as potential solutions for combating drug-resistant TB.
Anjali Negi, Summaya Perveen, Ria Gupta, Parvinder Pal Singh, Rashmi Sharma   +4 more
semanticscholar   +1 more source

A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment.

International journal of pharmaceutics
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (M.tb) and is the second leading cause of death from an infectious disease globally. The disease mainly affects the lungs and forms granulomatous lesions that encapsulate the bacteria, making ...
Suyash M. Patil, Alec M. Diorio, Parasharamulu Kommarajula, N. Kunda   +3 more
semanticscholar   +1 more source

Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline

Nature Communications
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to the first-line drugs isoniazid and rifampin, is a growing source of global mortality and threatens global control of tuberculosis disease.
Boatema Ofori-Anyinam, M. Hamblin, Miranda L. Coldren, Barry Li, G. Mereddy, M. Shaikh, A. Shah, Courtney Grady, N. Ranu, Sean Lu, P. Blainey, Shuyi Ma, James J. Collins, Jason H. Yang   +13 more
semanticscholar   +1 more source

Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.

Clinical Infectious Diseases
BACKGROUND Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration.
C. Padmapriyadarsini, Vikas Oswal, Chetankumar D Jain, M. Mariappan, N. Singla, Santosh Kumar, Bella Devaleenal Daniel, J. Dave, Parul Vadgama, B. Ramraj, Surya Kant, Anuj Bhatnagar, Sivakumar Shanmugam, D. Paul, Jeyadeepa Bharathi, Manasi Palav, Neha Shah, Rameshkumar Santhanakrishnan, R.K. Dewan, Nadim Shekh, P. Rathinam, Arvind B Sisara, Shubhangi Mankar, Jyoti Bajpai, Upasana Mittal, S. Chauhan, Ravinder Kumar, Mallik Parmar, Sanjay K Mattoo, Jyoti Jaju   +29 more
semanticscholar   +1 more source

Bedaquiline

Reactions Weekly
  +8 more sources

Bedaquiline Monotherapy for Multibacillary Leprosy.

New England Journal of Medicine
BACKGROUND Standard multidrug therapy for leprosy may be associated with severe side effects, which add to the stigma and discrimination that affect persons with the disease.
J. Barreto, P. Sammarco Rosa, Linda B Adams, Zuleima Aguilar, Nyasha Bakare, Sandra R Chaplan, Ruxandra Draghia Akli, Etienne Ernault, S. Kulke, Nacer Lounis, D. Millington, James A. Palmer, Bart Remmerie, Miao Wang, S. Young, Richard Truman, P. Rebello   +16 more
semanticscholar   +1 more source